Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for coronary plaque in overweight/obese CAD
NCT06606821Phase 4Recruiting
- Start
- Oct 2024
- Primary completion
- Mar 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronary artery disease (CAD) and atherosclerosis comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Change in Lipid Core Burden Index at 52 weeks. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
coronary artery disease (CAD)atherosclerosis
Beyond the preview
Go deeper on NCT06606821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06606821.